Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.61Sequent Scientific Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and good revenue and asset growth. However, profitability metrics present a mixed picture, with strong gross and operating margins, but challenges in net margin and return on equity. Efficiency ratios indicate areas needing improvement, particularly in managing inventory and receivables. Coverage ratios are weak, suggesting potential difficulties in meeting financial obligations. Overall, the company shows promise in growth and solvency but needs to enhance its profitability and operational efficiency to ensure long-term financial stability. The company's liquidity is average, providing it with the ability to meet its short-term obligations.
Health Score : 4.61Sequent Scientific Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company exhibits strong solvency and good revenue and asset growth. However, profitability metrics present a mixed picture, with strong gross and operating margins, but challenges in net margin and return on equity. Efficiency ratios indicate areas needing improvement, particularly in managing inventory and receivables. Coverage ratios are weak, suggesting potential difficulties in meeting financial obligations. Overall, the company shows promise in growth and solvency but needs to enhance its profitability and operational efficiency to ensure long-term financial stability. The company's liquidity is average, providing it with the ability to meet its short-term obligations.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
157.07
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
301.49
P/B RATIO
8.15
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
4.28
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-14.56
EV/EBITDA RATIO
38.81
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹262.3 as on Sep 1, 2026.
Growth Score : 6.00The company demonstrates strong growth in revenue and assets. However, the company is experiencing negative growth in earnings per share and net income. This suggests that while the company is increasing its sales and asset base, it is not translating into increased profitability. Careful cost management and revenue optimization strategies are essential to ensure sustainable growth.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.52 | 3.74 | 0.57 | -3.59 | 13.21 |
| Operating Profit Growth Rate | 24.71 | -48.58 | -88.99 | 408.33 | 165.57 |
| Earnings Per Share (EPS) Growth | 36.65 | -57.03 | -394.55 | 70.37 | 160.42 |
| Asset Growth Rate | 3.54 | 5.71 | 1.12 | 4.17 | |
| Net Income Growth Rate | 26.83 | -56.73 | -371.11 | 75.41 | 206.67 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 11 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 14 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 15 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 16 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 17 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 18 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 19 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 20 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 21 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 22 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 23 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Sequent Scientific Ltd. is India's largest animal health company, specializing in veterinary pharmaceuticals. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and finished dosage formulations for companion animals and livestock globally. With integrated operations spanning research, manufacturing, and distribution, Sequent holds a prominent market position in the animal health sector.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sequent Scientific Ltd's P/E ratio (TTM) is 157.07, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sequent Scientific Ltd's P/B ratio is 8.15, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sequent Scientific Ltd's P/S ratio is 4.28, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sequent Scientific Ltd's PEG ratio is -14.56.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sequent Scientific Ltd's EV/EBITDA ratio is 38.81.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sequent Scientific Ltd's ROE is 4.55%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sequent Scientific Ltd's ROA is 10.14%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sequent Scientific Ltd's ROCE is 8%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sequent Scientific Ltd's operating margin is 10.44%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sequent Scientific Ltd's net margin is 2.06%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sequent Scientific Ltd's current ratio is 1.71.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sequent Scientific Ltd's debt-to-equity ratio is 0.45.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sequent Scientific Ltd's interest coverage ratio is 1.72.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sequent Scientific Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sequent Scientific Ltd's EPS is 160.42.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹262.30. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1985 (as P.V.R. Murthy & Company Private Limited)
Headquarters: Bengaluru, Karnataka
Core Offerings: Veterinary APIs, Veterinary Formulations, Animal Health Supplements, Analytical Services
Stock Listing: NSE (SEQUENT), BSE (512529)
Promoter: The Carlyle Group
1985: Incorporated as P.V.R. Murthy & Company Private Limited.
2009: Merged with Strides Arcolab Limited's Animal Health API business.
2010: Demerged from Strides Arcolab to become Sequent Scientific Limited, focusing purely on animal health.
2013-2014: Expanded global footprint and product portfolio through strategic acquisitions, including stakes in Alvedita Vet (Turkey) and Bremer Pharma GmbH (Germany), and Lyka Labs' veterinary business.
2020: The Carlyle Group acquired a majority stake in Sequent Scientific, becoming the promoter.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Animal Health | 100% | Operating Profit |
Animal Health: Operates as a fully integrated animal health company, manufacturing both Active Pharmaceutical Ingredients (APIs) and finished dosage formulations for various animal species.
Global Presence: Products are marketed in over 100 countries, with significant operations in Europe, Latin America, and India through subsidiaries and a strong distribution network.
Research & Development: Focuses on developing new products and improving existing ones to address diverse animal health needs, supported by in-house R&D capabilities.
Manufacturing: Boasts state-of-the-art manufacturing facilities adhering to global regulatory standards (e.g., EU-GMP approved facilities for APIs and formulations).
Rajiv Malik (Chairman & Whole-time Director): An accomplished pharmaceutical industry veteran with over 35 years of experience, including a tenure as CEO of Dr. Reddy's Laboratories. Rajanarayana Thokala (Managing Director & CEO): Possesses over two decades of experience in the animal health industry, having previously held key leadership roles at global companies like Pfizer and Zoetis.
Alivira Animal Health Limited (India)
Bremer Pharma GmbH (Germany)
Aligned Animal Health SAS (France)
Sequent Scientific LLC (USA)
No major recent corporate actions on record.
The Sequent Scientific Ltd share price today is ₹262.30 on NSE (SEQUENT), as of 26 Sept 2026.
As of 26 Sept 2026, Sequent Scientific Ltd share price is ₹262.30, with previous close ₹262.30. Today's range is ₹262.30 to ₹262.30. The 52-week range is ₹N/A to ₹N/A.
As of today, Sequent Scientific Ltd's market cap is ₹6,636.19 crore (Mid Cap).
Sequent Scientific Ltd's current P/E ratio is 157.07, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.10.
Sequent Scientific Ltd's current P/B ratio is 8.15.
Sequent Scientific Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Sequent Scientific Ltd's EPS (TTM) is ₹160.42.
Sequent Scientific Ltd. is India's largest animal health company, specializing in veterinary pharmaceuticals. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and finished dosage formulations for companion animals and livestock globally. With integrated operations spanning research, manufacturing, and distribution, Sequent holds a prominent market position in the animal health sector.
Sequent Scientific Ltd is promoted by The Carlyle Group, holding 46.46% as of 26 Sept 2026.
Sequent Scientific Ltd is listed on NSE (SEQUENT) and BSE (512529). Its next quarterly results are expected on August 2024 (Q1 FY25).
Shareholding & Ownership Structure
